share_log

Bio-Techne's (NASDAQ:TECH) Investors Will Be Pleased With Their Notable 69% Return Over the Last Five Years

Bio-Techne's (NASDAQ:TECH) Investors Will Be Pleased With Their Notable 69% Return Over the Last Five Years

Bio-Techne(納斯達克股票代碼:TECH)的投資者將對過去五年69%的顯著回報感到滿意
Simply Wall St ·  05/25 01:45

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. But Bio-Techne Corporation (NASDAQ:TECH) has fallen short of that second goal, with a share price rise of 65% over five years, which is below the market return. The last year has been disappointing, with the stock price down 2.3% in that time.

當你長期購買和持有股票時,你肯定希望它能提供正回報。但不僅如此,你可能希望看到它的漲幅超過市場平均水平。但是Bio-Techne Corporation(納斯達克股票代碼:TECH)尚未實現第二個目標,股價在五年內上漲了65%,低於市場回報率。去年令人失望,當時股價下跌了2.3%。

So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.

因此,讓我們調查一下,看看公司的長期表現是否與基礎業務的進展一致。

In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

在他的文章中 格雷厄姆和多茲維爾的超級投資者 禾倫·巴菲特描述了股價如何並不總是合理地反映企業的價值。研究市場情緒如何隨着時間的推移而變化的一種方法是研究公司股價與其每股收益(EPS)之間的相互作用。

Over half a decade, Bio-Techne managed to grow its earnings per share at 9.9% a year. This EPS growth is reasonably close to the 11% average annual increase in the share price. That suggests that the market sentiment around the company hasn't changed much over that time. In fact, the share price seems to largely reflect the EPS growth.

在過去的五年中,Bio-Techne設法將其每股收益增長到每年9.9%。每股收益的增長相當接近股價年均增長11%。這表明,在那段時間內,公司周圍的市場情緒沒有太大變化。實際上,股價似乎在很大程度上反映了每股收益的增長。

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

下圖描述了 EPS 隨着時間的推移是如何變化的(點擊圖片可以看到確切的值)。

earnings-per-share-growth
NasdaqGS:TECH Earnings Per Share Growth May 24th 2024
納斯達克GS:科技股每股收益增長 2024 年 5 月 24 日

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Dive deeper into the earnings by checking this interactive graph of Bio-Techne's earnings, revenue and cash flow.

我們很高興地向大家報告,首席執行官的薪酬比資本相似公司的大多數首席執行官要適中。但是,儘管首席執行官的薪酬總是值得檢查的,但真正重要的問題是公司未來能否增加收益。查看這張Bio-Techne收益、收入和現金流的交互式圖表,深入了解收益。

What About Dividends?

分紅呢?

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. We note that for Bio-Techne the TSR over the last 5 years was 69%, which is better than the share price return mentioned above. The dividends paid by the company have thusly boosted the total shareholder return.

在考慮投資回報時,重要的是要考慮兩者之間的區別 股東總回報 (TSR) 和 股價回報。儘管股價回報率僅反映股價的變化,但股東總回報率包括股息的價值(假設已進行再投資)以及任何折扣融資或分拆的收益。可以公平地說,股東總回報率爲支付股息的股票提供了更完整的畫面。我們注意到,對於Bio-Techne而言,過去5年的股東總回報率爲69%,好於上述股價回報率。因此,該公司支付的股息提高了 股東回報。

A Different Perspective

不同的視角

Investors in Bio-Techne had a tough year, with a total loss of 1.9% (including dividends), against a market gain of about 28%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 11%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 1 warning sign for Bio-Techne that you should be aware of.

Bio-Techne的投資者經歷了艱難的一年,總虧損了1.9%(包括股息),而市場漲幅約爲28%。但是,請記住,即使是最好的股票有時也會在十二個月內表現不如市場。長期投資者不會那麼沮喪,因爲他們本可以在五年內每年賺11%。最近的拋售可能是一個機會,因此可能值得查看基本面數據以尋找長期增長趨勢的跡象。我發現將長期股價視爲業務績效的代表非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,我們已經確定了Bio-Techne的1個警告信號,你應該注意這一點。

If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.

如果你像我一樣,那麼你一定不想錯過這份內部人士正在買入的被低估的小盤股的免費清單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文引用的市場回報反映了目前在美國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論